Rivaroxaban is a new oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. It is approved in three indications in Europe: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.
In the US, Xarelto is approved for stroke prevention in AF patients and prevention of VTE in hip or knee surgery.
In total, Rivaroxaban is approved in more than 110 countries worldwide. This makes Rivaroxaban a future major player in the anticoagulants world.
STA®-Rivaroxaban Calibrator & Control is a new solution for the determination of Rivaroxaban concentration to support the examination of patients in different clinical situations.
Including Rivaroxaban calibrators and controls, this solution uses an anti-Xa method (STA®-Liquid Anti-Xa), insensitive to analytical and biological variables, with a wide working range.
Results are expressed in ng/mL of Rivaroxaban 
Reagents are offered with all the standard guarantees:
1. SAMAMA M.M. et al., Evaluation of the anti-factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls, ASH, 5071 b JN04, Abstract, 2010.